Rice Hall James & Associates LLC Takes $21.60 Million Position in Viridian Therapeutics, Inc. $VRDN

Rice Hall James & Associates LLC acquired a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,175,906 shares of the company’s stock, valued at approximately $21,601,000. Viridian Therapeutics comprises about 1.1% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 29th largest position.

A number of other institutional investors and hedge funds also recently made changes to their positions in VRDN. MetLife Investment Management LLC grew its holdings in Viridian Therapeutics by 0.8% during the fourth quarter. MetLife Investment Management LLC now owns 43,985 shares of the company’s stock valued at $1,369,000 after purchasing an additional 356 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Viridian Therapeutics by 0.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 139,360 shares of the company’s stock valued at $4,337,000 after buying an additional 380 shares during the last quarter. US Bancorp DE lifted its position in shares of Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock worth $53,000 after acquiring an additional 463 shares during the period. Bank of New York Mellon Corp boosted its stake in Viridian Therapeutics by 0.3% during the first quarter. Bank of New York Mellon Corp now owns 216,525 shares of the company’s stock worth $4,235,000 after buying an additional 659 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after acquiring an additional 876 shares in the last quarter.

Viridian Therapeutics Trading Up 4.6%

VRDN opened at $23.09 on Tuesday. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -6.85 and a beta of 0.91. The company’s 50 day moving average price is $19.16 and its two-hundred day moving average price is $21.16.

Viridian Therapeutics (NASDAQ:VRDN) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The business had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%. As a group, research analysts predict that Viridian Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Analyst Ratings Changes

VRDN has been the topic of several research analyst reports. Wells Fargo & Company raised shares of Viridian Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $20.00 to $31.00 in a research note on Monday, June 29th. Royal Bank Of Canada upped their target price on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday, August 7th. Wall Street Zen cut shares of Viridian Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, August 1st. Evercore set a $26.00 price target on Viridian Therapeutics in a research report on Friday, May 15th. Finally, Truist Financial lifted their price target on Viridian Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.93.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.